Wayzata, MN – January 2, 2008

Andcor places Chief Technical Officer and Vice President of Regulatory Affairs for HLT, Inc.

HLT, Inc., a high-tech cardiovascular device start-up developing a percutaneous aortic heart valve system, has named two members to its executive management team, appointing William Mirsch to become its chief technical officer and Jonas Runquist as its vice president of regulatory affairs.

Mirsch joins HLT from American Medical Systems, Inc. where he served as the business leader/R&D director for AMS' erectile restoration business. Prior AMS he was the director of research programs at St. Jude Medical's heart valve division. Bill began his career at Molecular Genetics, Inc. and received both his MS and BChE from the University of Minnesota.

Jonas Runquist comes to the company from Boston Scientific Corporation, Inc. where he was director of regulatory affairs for the company's peripheral interventions and vascular surgery business. Prior to BSCI he was the director of regulatory affairs for Myocor, Inc. In addition Jonas has held a variety of regulatory and product development management positions at Sulzer Spine-Tech, St. Jude Medical and Medtronic. Runquist holds a MBA from the University of St. Thomas and a BA from Hamline University.

In addition to the placements of Mirsch and Runquist Andcor has also partnered with HLT in identifying and hiring their director of product development, director of operations, director of quality systems and catheter development engineer.

About HLT

HLT, Inc. is an early stage company that is developing a percutaneously installed heart valve intended for the treatment of aortic valve disease. The HLT procedure is expected to be performed by an interventional cardiologist in a cardiac catheterization laboratory, and will be both less invasive and less costly than an open heart valve replacement procedure. The HLT system consists of a catheter based delivery system and a heart valve. The company has raised roughly $17 million to date.